Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Delayed Quote USD

Ionis Pharmaceuticals, Inc. (IONS)

Compare
27.90
+1.19
+(4.46%)
At close: 4:00:01 PM EDT
27.90
0.00
(0.00%)
After hours: 4:05:11 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
705,138
705,138
787,647
587,367
810,456
Cost of Revenue
11,215
11,215
9,133
14,116
10,842
Gross Profit
693,923
693,923
778,514
573,251
799,614
Operating Expense
1,169,030
1,169,030
1,132,225
983,442
814,353
Operating Income
-475,107
-475,107
-353,711
-410,191
-14,739
Net Non Operating Interest Income Expense
-90,457
-90,457
-81,497
-8,122
-9,300
Other Income Expense
105,464
105,464
101,222
160,328
-5,013
Pretax Income
-460,068
-460,068
-333,965
-257,985
-29,148
Tax Provision
-6,171
-6,171
32,321
11,737
-551
Net Income Common Stockholders
-453,897
-453,897
-366,286
-269,722
-28,597
Diluted NI Available to Com Stockholders
-453,897
-453,897
-366,286
-269,722
-28,597
Basic EPS
-2.44
-3.04
-2.56
-1.90
-0.20
Diluted EPS
-2.44
-3.04
-2.56
-1.90
-0.20
Basic Average Shares
145,928.25
149,514
143,000
142,000
141,000
Diluted Average Shares
145,928.25
149,514
143,000
142,000
141,000
Total Operating Income as Reported
-475,081
-475,081
-353,730
-410,191
-30,186
Total Expenses
1,180,245
1,180,245
1,141,358
997,558
825,195
Net Income from Continuing & Discontinued Operation
-453,897
-453,897
-366,286
-269,722
-28,597
Normalized Income
-556,664.43
-556,664.43
-434,989.14
-402,127.58
-33,253.81
Interest Expense
84,357
84,357
75,597
8,122
4,400
Net Interest Income
-90,457
-90,457
-81,497
-8,122
-9,300
EBIT
-375,711
-375,711
-258,368
-249,863
-24,748
EBITDA
-353,721
-353,721
-235,870
-227,758
-5,188
Reconciled Cost of Revenue
11,215
11,215
9,133
14,116
10,842
Reconciled Depreciation
21,990
21,990
22,498
22,105
19,560
Net Income from Continuing Operation Net Minority Interest
-453,897
-453,897
-366,286
-269,722
-28,597
Total Unusual Items Excluding Goodwill
104,121
104,121
86,966
167,602
4,747
Total Unusual Items
104,121
104,121
86,966
167,602
4,747
Normalized EBITDA
-457,842
-457,842
-322,836
-395,360
-9,935
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
1,353.57
1,353.57
18,262.86
35,196.42
90.19
12/31/2021 - 5/17/1991

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALNY Alnylam Pharmaceuticals, Inc.
237.77
+5.08%
 
ARWR Arrowhead Pharmaceuticals, Inc.
11.79
+6.12%
 
BMRN BioMarin Pharmaceutical Inc.
56.82
+0.89%
 
CYTK Cytokinetics, Incorporated
38.65
+2.11%
 
BBIO BridgeBio Pharma, Inc.
33.91
+4.95%
 
RNA Avidity Biosciences, Inc.
25.58
+6.10%
 
RARE Ultragenyx Pharmaceutical Inc.
34.14
+2.96%
 
SRRK Scholar Rock Holding Corporation
28.00
+6.42%
 
RVMD Revolution Medicines, Inc.
35.72
+6.09%
 
PCVX Vaxcyte, Inc.
31.20
+11.27%